Influence of APOE Gene Polymorphism on Interindividual and Interethnic Warfarin Dosage Requirement: A Systematic Review and Meta‐Analysis. Issue 5 (October 2016)
- Record Type:
- Journal Article
- Title:
- Influence of APOE Gene Polymorphism on Interindividual and Interethnic Warfarin Dosage Requirement: A Systematic Review and Meta‐Analysis. Issue 5 (October 2016)
- Main Title:
- Influence of APOE Gene Polymorphism on Interindividual and Interethnic Warfarin Dosage Requirement: A Systematic Review and Meta‐Analysis
- Authors:
- Yu, Wan‐ying
Sun, Xue
Wadelius, Mia
Huang, Lihua
Peng, Chen
Ma, Wan‐le
Yang, Guo‐Ping - Abstract:
- Summary: Background: Warfarin is the most extensively used coumarin anticoagulant. It has been shown that the anticoagulant effect of warfarin is associated with genetic variation. Apolipoprotein E (ApoE) is a possible candidate to influence the maintenance dose of warfarin. ApoE affects the vitamin K cycle by mediating the uptake of vitamin K into the liver. The vitamin K cycle is the drug target of warfarin. However, the association between genetic variants of the APOE gene and warfarin dose requirement is still controversial. Methods: Revman 5.3 software was used to analyze the relationship between APOE genotypes and warfarin dose requirements. Results: In our meta‐analysis, the E2/E2 genotype was significantly associated with warfarin dose. E2/E2 patients required 12% ( P = 0.0002) lower mean daily warfarin dose than E3/E3 carriers. In addition, subgroup analysis showed that Asians with the E4/E4 genotype tended to need lower warfarin maintenance doses, while the African American E4/E4 carriers needed slightly higher doses than E3/E3 carriers; however, these subgroups were very small. Conclusion: This is the first meta‐analysis of the association between APOE genotypes and warfarin dose. APOE E2/E2 might be one of the factors affecting warfarin dose requirements. The effect of APOE may vary between ethnicities.
- Is Part Of:
- Cardiovascular therapeutics. Volume 34:Issue 5(2016:Oct.)
- Journal:
- Cardiovascular therapeutics
- Issue:
- Volume 34:Issue 5(2016:Oct.)
- Issue Display:
- Volume 34, Issue 5 (2016)
- Year:
- 2016
- Volume:
- 34
- Issue:
- 5
- Issue Sort Value:
- 2016-0034-0005-0000
- Page Start:
- 297
- Page End:
- 307
- Publication Date:
- 2016-10
- Subjects:
- APOE -- Dose requirement -- Gene polymorphism -- Meta‐analysis -- Systematic review -- Warfarin
Cardiovascular pharmacology -- Periodicals
Cardiovascular agents -- Periodicals
Cardiovascular system -- Diseases -- Chemotherapy -- Periodicals
Cardiovascular Agents -- Periodicals
Cardiovascular Diseases -- drug therapy -- Periodicals
Agents cardiovasculaires -- Périodiques
Appareil cardiovasculaire -- Maladies -- Chimiothérapie -- Périodiques
616.1005 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1755-5922 ↗
http://www.blackwell-synergy.com/loi/cath ↗
http://www.blackwellpublishing.com/journal.asp?ref=1755-5914&site=1 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/1755-5922.12186 ↗
- Languages:
- English
- ISSNs:
- 1755-5914
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3051.520500
British Library HMNTS - ELD Digital store - Ingest File:
- 1079.xml